A randomized, double-blind, single-dose, parallel phase I clinical trial to compare the bioequivalence, immunogenicity, and safety of bevacizumab biosimilar and bevacizumab in healthy Chinese subjects
Zhengzhi Liu(The Affiliated Hospital to Changchun University of Chinese Medicine), Haimiao Yang(The Affiliated Hospital to Changchun University of Chinese Medicine), Zhenyue Gao(University of Science and Technology Beijing), Qiaohuan Deng(Changchun University of Chinese Medicine), Kaibo Xu(The Affiliated Hospital to Changchun University of Chinese Medicine), Zhengjie Su(Fujian Agriculture and Forestry University), Lixiu Zhang(Qingdao Agricultural University), Wei Yang(The Affiliated Hospital to Changchun University of Chinese Medicine), Nan Xiao(Jilin Academy of Agricultural Sciences), Shuang Yu(Zhengzhou University), Zeyu Wang(Anhui University), Yanli Wang(The Affiliated Hospital to Changchun University of Chinese Medicine), QU Dong-mei, Yicheng Zhao(Guangzhou University of Chinese Medicine), Qing Ren(Chinese University of Hong Kong), Yannan Zhou(The Affiliated Hospital to Changchun University of Chinese Medicine), Guangwen Liu(The Affiliated Hospital to Changchun University of Chinese Medicine)
Cited by 0
Related Papers
Glioma targeted therapy: insight into future of molecular approaches
|Molecular Cancer|2022|727
Regulatory mechanisms of immune checkpoints PD-L1 and CTLA-4 in cancer
|Journal of Experimental & Clinical Cancer Research|2021|535
Advances in the Application of Perovskite Materials
|Nano-Micro Letters|2023|408
Immune checkpoint modulators in cancer immunotherapy: recent advances and emerging concepts
|Journal of Hematology & Oncology|2022|273